Autologous Peripheral Blood Stem Cell Transplantation With In Vivo Purging as an Alternate Stem Cell Transplantation Program for Pts w/AML in 1st & 2nd Complete Remission w/no HLA Matched Related Donor
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00531583 |
Recruitment Status
:
Completed
First Posted
: September 19, 2007
Last Update Posted
: January 5, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Leukemia, Monocytic, Acute | Drug: Autologous peripheral Bld Stem Cell Transplantation with In Vivo Purging as an alternate stem cell transplantation | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 350 participants |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Autologous Peripheral Blood Stem Cell Transplantation With In Vivo Purging as an Alternate Stem Cell Transplantation Program for Pts w/AML in 1st & 2nd Complete Remission w/no HLA Matched Related Donor |
Study Start Date : | March 2001 |
Actual Primary Completion Date : | June 2015 |
Actual Study Completion Date : | June 2015 |
-
Drug: Autologous peripheral Bld Stem Cell Transplantation with In Vivo Purging as an alternate stem cell transplantation
- Efficacy [ Time Frame: 2009-2015 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 85 Years (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with AML in 1st & 2nd complete remission w/no HLA matched related donor

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00531583
Saudi Arabia | |
KFSH&RC | |
Riyadh, Saudi Arabia, 1211 |
Principal Investigator: | Fahad AlMohareb | KFSH&RC |
Responsible Party: | King Faisal Specialist Hospital & Research Center |
ClinicalTrials.gov Identifier: | NCT00531583 History of Changes |
Other Study ID Numbers: |
RAC#2001-004 |
First Posted: | September 19, 2007 Key Record Dates |
Last Update Posted: | January 5, 2016 |
Last Verified: | January 2016 |
Keywords provided by King Faisal Specialist Hospital & Research Center:
AML in 1st & 2nd complete remission w/no HLA matched related donor |
Additional relevant MeSH terms:
Leukemia, Monocytic, Acute Leukemia, Myeloid, Acute Leukemia, Myeloid |
Leukemia Neoplasms by Histologic Type Neoplasms |